Utilize este identificador para referenciar este registo:
https://hdl.handle.net/10316/275
Título: | CA-125 AUC as a new prognostic factor for patients with ovarian cancer | Autor: | Mano, Antonio Falcão, Amílcar Godinho, I. Santos, J. Leitão, F. Oliveira, C. Caramona, M. |
Palavras-chave: | neoplasias do ovario; prognostico; marcadores tumorais; farmacocinética; CA 125 | Data: | Mai-2005 | Editora: | Elsevier | Citação: | Gynecologic Oncology 97:2 (2005) 529-534 | Resumo: | Abstract Objective The aim of the present study was to investigate the usefulness of the CA-125 area under the curve (AUC) as a new kinetic parameter for predicting overall survival in patients with ovarian cancer. In addition, the relationship of CA-125 AUC with other prognostic factors of ovarian cancer was evaluated. Methods Ninety-two patients that underwent primary line chemotherapy within 4 months after submission to cytoreductive surgery were included. For each patient, CA-125 AUC was calculated and a statistical analysis was conducted to compare CA-125 AUC behavior among patients according to several covariates. Results The mean age at diagnostic time was found to be 55.5 (16.1–82.4) years with a mean survival of 39.2 (3.5–100.1; SE = 2.6) months. Across FIGO stage I, II, III, and IV patients had a mean CA-125 AUC of 18.2, 24.6, 147.8, and 574.6 IU/ml*days, respectively (P < 0.05). At the evaluation date, living patients had a mean CA-125 AUC of 40.1 in contrast to 234.1 IU/ml*days (P < 0.05) for deceased ones. Patients with a complete response to primary chemotherapy had a mean CA-125 AUC of 48.8, while patients with a partial response had a mean of 251.7 IU/ml*days, and patients with no response or disease progression had a mean of 316.5 IU/ml*days (P < 0.05). The best CA-125 AUC performance is in predicting patient complete response to chemotherapy with a cut-off of 100 IU/ml*days and an accuracy of 82%. Conclusions Despite CA-125 AUC high correlation with the FIGO stage, residual disease, and patient final outcome, the main interest of CA-125 AUC calculation is to evaluate the treatment efficacy and to foresee a full chemotherapy response. Further studies should be carried out before extrapolating these results to other data sets. | Descrição: | Prémio atribuído pelo International Research Promotion Council a Amílcar C. Falcão: Eminent Scientist of the Year 2006. Europe | URI: | https://hdl.handle.net/10316/275 | ISSN: | 0090-8258 | DOI: | 10.1016/j.ygyno.2005.01.040 | Direitos: | openAccess |
Aparece nas coleções: | FFUC- Artigos em Revistas Internacionais |
Ficheiros deste registo:
Ficheiro | Descrição | Tamanho | Formato | |
---|---|---|---|---|
CA-125.pdf | 239.33 kB | Adobe PDF | Ver/Abrir |
Todos os registos no repositório estão protegidos por leis de copyright, com todos os direitos reservados.